A Phase 1/2 interventional study of Bendavia and Placebo in Renal Artery Obstruction, Hypertension, Renovascular and Ischemia Reperfusion Injury, sponsored by Stealth BioTherapeutics Inc.. Terminated at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by Stealth BioTherapeutics Inc. · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Renal Artery Obstruction with a site in United States — none open to participants now, none under way, none of them phase 3. Renal Artery Obstruction · United States.
Among the 16 studies in Renal Artery Obstruction with a site in United States, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2012, is the only one in phase 1/2, and was the 13th registered.
59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.
Browse Renal Artery Obstruction studies →None of the 16 studies in Renal Artery Obstruction with a site in United States is open now. The open studies under Renal Artery Obstruction, anywhere →
Of the 7 Renal Artery Obstruction studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 1992; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 100 across 42 interventional studies indexed under Renal Artery Obstruction.
Median enrollment 64 across the 14 interventional studies, 75 across the 1 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 1 study filed under Renal Artery Obstruction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Renal Artery Obstruction with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with Atherosclerotic Renal Artery Stenosis (ARAS), who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA).
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with ARAS, who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA).
The randomization (1:1 active:placebo) was stratified by a diagnosis of diabetes mellitus. Participants received either 0.05 mg/kg/h elamipretide or matching placebo, administered as an IV infusion at 60 mL/h infused 30 minutes before and continued 3 hours after PTRA of the renal artery. After completion of the PTRA and stenting, subjects were to receive standard treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
Drug: Bendavia
Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
Drug: Placebo
Also known as: MTP-131, Elamipretide
Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.
Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..
Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.
Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.
Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA
Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.
Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA
Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys
Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA
Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.
Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.
Time frame: Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA
Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA
Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.
Time frame: Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA
Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA
Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia
Time frame: 27H post PTRA and 8 weeks Post PTRA
Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA
Time frame: Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA
Mean Change in Diastolic Blood Pressure
Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.
Time frame: Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA
| Milestone | Bendavia | Placebo |
|---|---|---|
| Started | 7 | 9 |
| Completed | 6 | 8 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..
| mL/min | Bendavia | Placebo |
|---|---|---|
| Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA. | 6.3 ± 12.14 | 12.0 ± 23.84 |
Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.
| mL/min | Bendavia | Placebo |
|---|---|---|
| Right Single Kidney | 0.238 ± 0.2557 | 0.010 ± 0.0552 |
| Left Single Kidney | 0.012 ± 0.1487 | 0.120 ± 0.1600 |
Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.
| mL/min | Bendavia | Placebo |
|---|---|---|
| Right Cortical | 1.266 ± 0.9341 | -0.816 ± 0.6614 |
| Right Medullary | 0.242 ± 0.4143 | -0.082 ± 0.2541 |
| Left Cortical | 0.614 ± 1.2390 | 0.220 ± 0.9112 |
| Left Medullary | 0.150 ± 0.3788 | 0.156 ± 0.5184 |
Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys
| mL/min | Bendavia | Placebo |
|---|---|---|
| Right Cortical | 85.056 ± 63.2943 | -28.406 ± 54.8919 |
| Right Medullary | 6.658 ± 20.3007 | -10.204 ± 21.2044 |
| Right Total | 91.712 ± 82.4794 | -38.608 ± 43.4011 |
| Left Cortical | 23.928 ± 64.4891 | 35.090 ± 59.9470 |
| Left Medullary | 3.610 ± 14.4951 | 5.930 ± 19.0256 |
| Left Total | 27.538 ± 78.0728 | 41.018 ± 75.6824 |
Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.
| mL | Bendavia | Placebo |
|---|---|---|
| Right Total Kidney Volume | 1.270 ± 12.8218 | 4.708 ± 13.7198 |
| Left Total Kidney Volume | 5.090 ± 17.6951 | 10.220 ± 8.9447 |
| Right Cortical | 4.372 ± 10.5438 | 9.840 ± 13.1156 |
| Right Medullary | -3.162 ± 4.7616 | -5.132 ± 7.0670 |
| Left Cortical | 4.534 ± 15.0459 | 10.100 ± 10.8462 |
| Left Medullary | 0.558 ± 3.1016 | 0.120 ± 8.6277 |
Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.
| s^-1 | Bendavia | Placebo |
|---|---|---|
| AxialRightPrefurosemideFractHyp%>20 27H Post PTRA | 13.440 ± 34.6825 | 16.708 ± 19.4980 |
| AxialRightPrefurosemideFractHyp%>20; 8Wk Post PTRA | -3.380 ± 8.5013 | -10.892 ± 15.370 |
| AxialRightPrefurosemideFractHyp%>30 27H PostPTRA | 5.206 ± 9.4875 | 11.600 ± 17.8192 |
| AxialRightPrefurosemideFractHyp%>30 8Wk PostPTRA | -2.120 ± 2.7426 | -1.840 ± 2.8693 |
| AxialRightPostfurosemideFracHyp%>20 27HPostPTRA | 24.280 ± 27.6206 | 13.854 ± 26.2292 |
| AxialRightPostfurosemideFracHyp%>20 8WkPostPTRA | 28.625 ± 8.9537 | -7.560 ± 13.5471 |
| AxialRightPostfurosemideFracHyp %30 27H Post PTRA | 6.080 ± 7.6904 | 13.490 ± 21.1322 |
| AxialRightPostfurosemideFracHyp%>30 8WkPost PTRA | -0.400 ± 2.9473 | -1.370 ± 3.4412 |
| AxialLeftPrefurosemide Frac Hyp%>20 27H Post PTRA | 1.320 ± 21.7694 | 12.767 ± 26.0745 |
| AxialLeftPrefurosemide Frac Hyp%>20 8Wk Post PTRA | -0.420 ± 17.3066 | -8.160 ± 16.4477 |
| AxialLeft Prefurosemide Frac Hyp %>30 27H PostPTRA | -3.128 ± 3.0154 | 16.938 ± 25.4089 |
| AxialLeft PrefurosemideFrac Hyp %>30 8Wk PostPTRA | -0.602 ± 7.1510 | -6.360 ± 11.3054 |
| AxialLeft Post-FurosemideFrac Hyp%>20 27HPostPTRA | 0.148 ± 21.0184 | 14.083 ± 34.6825 |
| AxialLeft Post-FurosemideFrac Hyp%>20 8WkPostPTRA | -0.012 ± 17.3829 | -14.220 ± 13.303 |
| AxialLeft Post-FurosemideFrac Hyp%>30 27HPostPTRA | -1.874 ± 2.5111 | 18.757 ± 27.1441 |
| AxialLeft Post-FurosemideFrac Hyp%>30 8WkPostPTRA | 1.858 ± 7.0087 | -5.704 ± 8.3550 |
Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia
| s^-1 | Bendavia | Placebo |
|---|---|---|
| CoronalRtFractHypoxia% >20Prefuros.27HPost-PTRA | 20.314 ± 33.3525 | 9.083 ± 17.3368 |
| CoronalRtFractHypoxia% >20Prefuros.8WkPost-PTRA | 4.140 ± 16.4690 | -2.220 ± 7.5549 |
| CoronalRtFractHypoxia% >30Prefuros.27HPost-PTRA | 10.800 ± 9.6734 | 9.250 ± 30.6001 |
| CoronalRtFractHypoxia% >30Prefuros8WkPost-PTRA | 3.300 ± 10.1403 | -2.852 ± 11.1986 |
| CoronalRtFractHypoxia% >20Postfuros27HPost-PTRA | 29.800 ± 33.5328 | 3.840 ± 22.4825 |
| CoronalRtFractHypoxia% >20Postfuros8WKPost-PTRA | 5.233 ± 7.5142 | -5.220 ± 4.6018 |
| CoronalRtFractHypoxia% >30Postfuros27HPost-PTRA | 12.875 ± 13.2666 | 11.458 ± 32.8826 |
| CoronalRtFractHypoxia% >30Postfuros8WkPost-PTRA | 2.233 ± 3.5119 | -8.158 ± 16.5393 |
| CoronalLeftFractHypoxia% >20Prefuros.27HPost-PTRA | 5.000 ± 23.7674 | 6.033 ± 31.1820 |
| CoronalLeftFractHypoxia% >20Prefuros.8WkPost-PTRA | -3.125 ± 10.2970 | -0.525 ± 12.5077 |
| CoronalLeftFractHypoxia% >30Prefuros.27HPost-PTRA | -2.000 ± 8.9272 | 22.615 ± 35.6971 |
| CoronalLeftFractHypoxia% >30Prefuros.8WkPost-PTRA | -2.275 ± 4.4650 | -1.525 ± 12.3605 |
| CoronalLeftFractHypoxia% >20Postfuros.27HPost-PTRA | 6.240 ± 24.5671 | 6.783 ± 29.1337 |
| CoronalLeftFractHypoxia% >20Postfuros.8WkPost-PTRA | 3.375 ± 9.2525 | -0.700 ± 14.7384 |
| CoronalLeftFractHypoxia% >30Postfuros.27HPost-PTRA | 0.080 ± 7.3145 | 20.345 ± 31.5024 |
| CoronalLeftFractHypoxia% >30Postfuros.8WkPost-PTRA | -0.250 ± 2.0873 | -4.225 ± 12.7899 |
| mmHg | Bendavia | Placebo |
|---|---|---|
| 27 Hours Post-PTRA | -2.9 ± 14.78 | -3.8 ± 15.69 |
| 8 weeks Post PTRA | 13.2 ± 19.88 | -0.8 ± 30.83 |
Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.
| mmHg | Bendavia | Placebo |
|---|---|---|
| 27 Hours Post-PTRA | 3.6 ± 7.76 | -2.0 ± 9.88 |
| 8 Weeks Post PTRA | 0.0 ± 9.70 | 0.1 ± 9.80 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bendavia | 0/7 (0%) | 1/7 (14.3%) | 2/7 (28.6%) |
| Placebo | 0/9 (0%) | 1/9 (11.1%) | 5/9 (55.6%) |
| Event | Bendavia | Placebo |
|---|---|---|
| Vascular PseudoaneurysmInjury, poisoning and procedural complications | 1/7 | 0/9 |
| Cardiac Failure AcuteCardiac disorders | 0/7 | 1/9 |
| Event | Bendavia | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 0/7 | 2/9 |
| Respiratory DistressRespiratory, thoracic and mediastinal disorders | 0/7 | 2/9 |
| HypertensionVascular disorders | 1/7 | 1/9 |
| HypotensionVascular disorders | 1/7 | 1/9 |
| Blood sodium decreasedInvestigations | 1/7 | 1/9 |
| ContusionInjury, poisoning and procedural complications | 1/7 | 0/9 |
| DizzinessNervous system disorders | 1/7 | 0/9 |
| Oedema peripheralGeneral disorders | 1/7 | 0/9 |
| Labile Blood PressureVascular disorders | 0/7 | 1/9 |
| Blood magnesium decreasedInvestigations | 0/7 | 1/9 |
| Age, Continuous(years) | Bendavia | Placebo | Total |
|---|---|---|---|
| Mean | 66.1 ± 6.41 | 72.6 ± 7.78 | 69.8 ± 7.72 |
| Sex: Female, Male(Participants) | Bendavia | Placebo | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 3 | 6 | 9 |
| Diabetes Mellitus Status(Participants) | Bendavia | Placebo | Total |
|---|---|---|---|
| Positive | 0 | 3 | 3 |
| Negative | 7 | 6 | 13 |
The record gives a start of Dec 2012, a primary completion of Dec 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →